Literature DB >> 14513112

[Rheumatoid arthritis and atherosclerosis].

B Seriolo1, A Sulli, A Burroni, M Cutolo.   

Abstract

Evidence continue to accumulate indicating that patients with rheumatoid arthritis (RA) present an increased risk of cardiovascular disease (and death). The risk factors for coronary artery disease (CAD) in RA are not fully understood. However, a number of possible factors have been described, but more than one may be efficient, such as homocysteine, presence of antiphospholipid antibodies, altered serum levels of selected lipoproteins, and all together may have implications for the atherogenesis observed in these patients. Other factors that may facilitate this process, include corticosteroid use, methotrexate therapy and hormonal factors. However, the relative importance of these specific risk factors for the atherogenesis in this disease is poorly known. Recent findings indicate that cardiac death is increased in RA patients when compared with subjects without arthritis and that generally, the inflammatory process may contribute to atherosclerosis. In addition, other studies indicate that serum concentration of pro-inflammatory cytokines are found elevated at baseline, among patients at risk for future coronary occlusion.

Entities:  

Mesh:

Year:  2003        PMID: 14513112     DOI: 10.4081/reumatismo.2003.140

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  2 in total

1.  Prevalence of antiphospholipid antibodies in Chilean patients with rheumatoid arthritis.

Authors:  Iván Palomo; Carmen Pinochet; Marcelo Alarcón; Rodrigo Sandoval; Jaime Gonzalez; Francisco Monsalves; Ricardo Forastiero
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Intervention of integrative medicine treatment has impact on serum levels of ET-1, TNF-α, MLT in RA-CVD.

Authors:  Meng Chen; Zhenbin Li; Zheng Zhang; Yong Du; Yingjie Zhang; Minghua Xu; Caixia Sun
Journal:  Saudi J Biol Sci       Date:  2018-05-14       Impact factor: 4.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.